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Hemangiopericytoma (HPT) is a rare mesenchymal tumor of fibroblastic type and for its rarity is poorly studied. The most
common sites of metastatic disease in patients with intracranial HPT are the bone, liver, and lung, suggestive for an
hematogenous dissemination; for this reason, we investigated, for the first time, the presence of circulating tumor cells (CTCs)
in hemangiopericytoma patient by CellSearch® and SceenCell® devices. Peripheral blood samples were drawn and processed by
CellSearch, an EpCAM-dependent device, and ScreenCell®, a device size based. We found nontypical CTCs by CellSearch
system and the immunofluorescence analysis performed on CTCs isolate by ScreenCell demonstrated the presence of single
CTCs and CTC clusters. The molecular characterization of single CTCs and CTC clusters, using antibodies directed against
EpCAM, CD34, cytokeratins (8, 18, and 19), and CD45, showed a great heterogeneity in CTC clusters. We believe that the
present study may open a new scenario in the rare tumors: the introduction of the liquid biopsy and the molecular
characterization of circulating tumor cells could lead to personalized targeted treatments and also for rare tumors.
1. Introduction
Hemangiopericytoma (HPT) is a rare mesenchymal tumor of
fibroblastic type [1]. Although originally presumed to origi-
nate from vascular pericytes [2], the precise histogenesis
has not been definitely established. From a mere clinical
point of view, HPT represents an unpredictable disease, since
distant relapses are usually delayed and may occur even
decades after diagnosis of the primary tumors [3], suggesting
that a long-term follow-up is strongly needed [4]. Treatments
are limited so far also due to inadequate funding for preclin-
ical and clinical research programmes, and new strategies are
mandatory in order to allow the earlier detection of tumor
recurrence and metastasis, thus improving the diagnosis,
treatment, and surveillance of patients. The most common
sites of metastatic disease in patients with intracranial HPT
are the bone, liver, and lung, suggestive for an hematogenous
dissemination [5]. Circulating tumor cells (CTCs) represent
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a unique source of information about hematogenous spread
of tumors and are recognised as a useful tool in the identifi-
cation of new clinically relevant biomarkers [6]. Although
CTCs have been mainly isolated from carcinomas through
epithelial antigen-targeted antibodies (EpCAM), reports
have demonstrated that EpCAM expression is not restricted
to epithelial-derived tumors, but shared as well by CTCs iso-
lated from patients with mesenchymal-derived cancers [7].
In the present study, we sought to investigate the feasibility
to isolate CTCs from a patient with secondary liver heman-
giopericytoma using CellSearch system, the only FDA-
approved for CTCs enumeration. CellSearch captures cells
using a monoclonal antibody specific to EpCAM and
identifies CTCs using differential fluorescent antibodies to
detect the presence of cytokeratins (CK) within a nucleus-
containing intact cell and absence of CD45, as defining
characteristics of CTCs (DAPI+/CK+/EpCAM+/CD-45-).
2. Materials and Methods
2.1. Circulating Tumor Cells Detection. Circulating tumor
cells were detected through two methods, one EpCAM-
dependent (CellSearch) and the other size based (ScreenCell).
Peripheral blood samples were drawn after informed consent
into two tubes, after discarding the first milliliters to avoid
contamination with cutaneous epithelial cells taken by the
needle during the sampling. 7.5mL of blood was collected
in CellSave preservative tube (Menarini Silicon Biosystems,
Castel Maggiore, Bo, Italy) and processed by CellSearch
(Menarini Silicon Biosystems), employing CellSearch CTC
kit, according to manufacturer’s instructions. Six milliliters
of blood was collected in tube containing K2EDTA and proc-
essed by ScreenCell Cyto kit (ScreenCell, Sarcelles, France) to
isolate fixed cells for cytological studies. Briefly, in order to fix
the cells and lyse red blood cells, 3mL of blood was diluted in
4mL of FC2 filtration buffer (ScreenCell). After 8min of
incubation at room temperature, 7mL of diluted sample
was added into device tank and filtered under a pressure gra-
dient using a vacutainer tube. After washing with PBS to
remove red blood cells debris, the filter was left on absorbing
paper to dry at room temperature and then stored at −20°C.
The filtration was carried out in duplicate and completed
within 3min.
2.2. Immunofluorescence Analysis on CTCs. For immunoflu-
orescence, nonspecific protein binding was blocked by 5%
normal goat serum. Specimens were permeabilized in PBS-
Tween 20 (PBS-T) for 20min.
Protocol 1: the filter was first incubated overnight at 4°C
with primary mouse monoclonal anti-EpCAM (VU1D9;
1 : 50; Invitrogen Ltd., Paisley, UK) antibody and then, after
washing twice with PBS-T, probed for 1 h with antimouse
AlexaFluor-488 secondary antibody (1 : 50, Invitrogen).
Next, section was incubated overnight at 4°C with staining
solution of phycoerythrin- (PE-) conjugated cytokeratins
(CK) 8, 18, and 19 and allophycocyanin- (APC-) conjugated
CD45 antibodies (CellSearch CTC kit). Nuclei were counter-
stained with 4′,6-diamidino-2′-phenylindole (DAPI).
Protocol 2: the filter was first incubated overnight at 4°C
with primary mouse monoclonal anti-EpCAM and rabbit
polyclonal anti-CD45 (1 : 50; Cell Signaling Technology,
Danvers, MA, USA) antibodies and then, after washing twice
with PBS-T, probed for 1 h with antimouse AlexaFluor-350
and antirabbit AlexaFluor-594 (1 : 50; Invitrogen) secondary
antibodies. Next, section was incubated overnight at 4°C with
CD34 class III/FITC (Dako North America Inc., Carpinteria,
CA, USA). Finally, specimen was counterstained with
DRAQ5 (Cell Signaling Technology), a cell permeable far-
red fluorescent DNA dye, for visualization of cell nuclei.
All primary antibodies were diluted in 1% bovine serum
albumin in PBS-T.
The filters were scanned by a digital scanner (Aperio
ScanScope FL System, Aperio Technologies, Inc., Oxford,
UK) and were also analyzed by confocal microscopy (Leica
TCS-SP2).
CTC clusters were defined as groups of CTCs containing
≥3 distinct nuclei according to previous publication [8]. In
representative images, different pseudocolors were arbitrarily
assigned, irrespectively to the actual fluorophore, to each of
the four fluorescence channels and changed to optimize the
visualization of the different signals. When displayed in the
image, the nuclei were always showed in blue.
3. Results and Discussion
According to the mesenchymal nature of hemangiopericy-
toma, we failed to detect typical epithelial-like CTCs, but
we were able to identify 5 DAPI+/EpCAM+/CK-/CD45-
events, which might be referable to cells with nonepithelial
features. According to the CellSearch guidelines, all objects
with no clear cytokeratin staining are defined as “suspicious
objects.” Similar events have been previously described by
our group to have prognostic significance in other cancer
types, such as renal cell carcinoma, frequently lacking cyto-
keratin expression [9]. In order to better characterize these
atypical CTCs, we processed a second blood sample by using
ScreenCell, a device that allows a size-selective separation of
CTCs from other blood cells. To evaluate the molecular pro-
file of atypical CTCs, an immunofluorescence staining was
performed on two filters obtained from the blood of the
patient, using in the first one the same antibodies used in
the CellSearch system (EpCAM, CK, and CD-45, as defin-
ing characteristics of CTCs) and in the second one CD34
(as hemangiopericytoma specific marker) (Figure 1) [10, 11].
In both the examined filters, single or clustered CTCs were
identified and an average of one cluster per filter was observed.
CTCs were variably round or elongated, presented a high
nucleus to cytoplasm ratio, scant cytoplasm, and an oval
nuclei. In examined filters, both single and clustered CTCs
were found positive for EpCAM but negative for CD45.
EpCAM expression was localized at the cell surface in single
cells, but retained in the internal part of the clusters. The
absence of EpCAM at the cluster surface might explain the
failure of CellSearch to detect CTC clusters, as already demon-
strated in epithelial-like tumors, such as nonsmall cell lung
cancer [12]. EpCAM-positive clusters variably expressed CK
but were constantly negative for CD45 and positive for
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CD34. Some studies have demonstrated that CTC clusters are
composed of a number of tumor cellsmixed to nontumor cells
such as mesenchymal cells, epithelial cells, pericytes, immune
cells, platelets, and cancer-associated fibroblasts [13]. In our
patient, the coexpression of EpCAM, CK, and CD34 within
the CTC cluster confirms the great heterogeneity in CTC clus-
ters and their patent multifaceted composition. The feasibility
of a liquid biopsy in a rare tumor, such as HPC, might have
several crucial clinical implications. First, most intracranial
meningeal HPCs resemble meningiomas in their clinical
presentation and histological features and may therefore be
misdiagnosed, despite important differences in prognosis
[14]. Keeping scanning and following up with a noninvasive
tool, such as a blood draw, mightmake the difference. Second,
systemic therapyoptions forHPCare limited so far, anddue to
the increasing number of targeted therapies available, the
molecular characterization of CTCs has the unique potential
to translate into personalized treatments [15]. To this pur-
pose, clinical trials on rare cancers are not usually performed
due to the small numbers of eligible patients, and while more
common cancers are increasingly being treated according to
a biomarker-driven approach, the “one size fits all” approach
is still the standard of care for rare tumors. Personalized
targeted treatments need to be developed specifically for
hemangiopericytoma as well as in all other rare cancers,
and liquid biopsy has certainly the right credentials to
facilitate this process.
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Figure 1: Phenotype of circulating tumor cells isolated using ScreenCell Cyto kit. In representative images, nuclei are displayed in blue.
Pseudocolors were changed for each of the four channels to optimize the visualization of the different signals. (a) Immunofluorescence for
CD34, EpCAM, and CD45. Clusters of CD45- cells coexpressing EpCAM and CD34 are displayed. (b) and (c) Immunofluorescence for
EpCAM, cytokeratins (CK) 8, 18, and 19, and CD45. Single CD45-/CK- cells expressing EpCAM (b). Cluster of CD45- cells coexpressing
EpCAM and CK (c).
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